<DOC>
	<DOCNO>NCT00716534</DOCNO>
	<brief_summary>This study design determine clinical efficacy toxicity ABT-869 combination carboplatin paclitaxel treatment subject advance metastatic NSCLC .</brief_summary>
	<brief_title>Study Carboplatin/Paclitaxel Combination With ABT-869 Subjects With Advanced Metastatic Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Subject must least 18 year age . Subject must cytologically histologically confirm nonsquamous NSCLC Subject must recurrent advanced ( Stage IIIb pleural pericardial effusion ) metastatic ( Stage IV ) disease amenable surgical resection radiation curative intent . Subject measurable disease , define least 1 unidimensional measurable lesion compute tomography ( CT ) scan define RECIST ( subject randomize portion ) . Subject ECOG Performance Score 01 . Willing take adequate measure prevent pregnancy . The subject NSCLC predominant squamous cell histology Subject hypersensitivity paclitaxel . Subject receive anticancer therapy treatment NSCLC . Subject receive radiation therapy within 21 day Study Day 1 . Subject major surgery within 21 day . Subject untreated brain meningeal metastasis . Subject receive therapeutic anticoagulation therapy . Subject central thoracic tumor lesion define location within hilar structure . Subject proteinuria CTC Grade &gt; 1 baseline . Subject history , currently exhibit clinically significant cancer relate event bleed . The subject currently exhibit symptomatic persistent , uncontrolled hypertension define diastolic blood pressure ( BP ) &gt; 90 mm Hg systolic BP &gt; 140 mm Hg . The subject history myocardial infarction , stroke Transient Ischemic Attack ( TIA ) within 6 month Study Day 1 . The subject document leave ventricular ( LV ) ejection fraction &lt; 50 % . The subject know autoimmune disease renal involvement ( i.e. , lupus ) . The subject receive combination antiretroviral therapy HIV . The subject clinically significant uncontrolled condition ( ) . The subject history another active cancer within past 5 year . The subject active ulcerative colitis , Crohn 's disease , celiac disease condition interfere absorption . The subject medical condition , opinion study investigator place unacceptably high risk toxicity . The subject pregnant breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>